Japan has officially launched a public comment period for its landmark cannabis reform bill, offering new details on how its nascent cannabis industry will look over the coming months.
On May 30, the Japanese government announced that it would now be accepting public comments from interested parties on five measures of the new bill.
Most notably, the preliminary proposals suggest that Japan is seeking to forgo the complex and lengthy Novel Foods process for CBD products, and could become the first country to approve CBD in food.
Yves Antoniazzi, Managing Director of Astrasana Holding AG, one of the few international companies to have a foothold in the Japanese CBD market, said: “We have been waiting a long time for this. It is a huge milestone for the global cannabis industry. Japan is the one of the first countries to approve CBD in food, paving the way for corporate companies to list CBD products in retail chains.”
Business of Cannabis will be digging deeper into the details of Japan’s new proposals and providing analysis into their implications for businesses in the coming days.
What happened?
Late last year, Japan made a major step towards cannabis reform after approving a bill to amend its 75-year-old Cannabis Control Act.
After passing the bill in November, the Japanese authorities have been ironing out the details of these reforms, and the industry has been poised for an announcement from the Ministry of Health, Labour and Welfare (MHLW) laying out the new framework.
The public comment period, which will last until June 13 or 29, offers medical professionals and CBD businesses the opportunity to examine the draft order and voice their concerns before a final decision is made and the amendments can be enacted.
Opinions are now being solicited on five topics, including law enforcement, THC analysis methods, the development of related laws and regulations, and first and second-class cultivation license reviews.
As previously reported, the bill is set to amend a few key measures which could enable the country’s CBD and medical cannabis industries to flourish.
Primarily, while Japan already has a booming CBD industry, it currently only allows products with no trace THC. This is expected to change, and initial reports suggest this could rise to 0.3%.
‘Huge Milestone’ as Japan Moves Ahead With Cannabis Reform
Japan has officially launched a public comment period for its landmark cannabis reform bill, offering new details on how its nascent cannabis industry will look over the coming months.
On May 30, the Japanese government announced that it would now be accepting public comments from interested parties on five measures of the new bill.
Most notably, the preliminary proposals suggest that Japan is seeking to forgo the complex and lengthy Novel Foods process for CBD products, and could become the first country to approve CBD in food.
Yves Antoniazzi, Managing Director of Astrasana Holding AG, one of the few international companies to have a foothold in the Japanese CBD market, said: “We have been waiting a long time for this. It is a huge milestone for the global cannabis industry. Japan is the one of the first countries to approve CBD in food, paving the way for corporate companies to list CBD products in retail chains.”
Business of Cannabis will be digging deeper into the details of Japan’s new proposals and providing analysis into their implications for businesses in the coming days.
What happened?
Late last year, Japan made a major step towards cannabis reform after approving a bill to amend its 75-year-old Cannabis Control Act.
After passing the bill in November, the Japanese authorities have been ironing out the details of these reforms, and the industry has been poised for an announcement from the Ministry of Health, Labour and Welfare (MHLW) laying out the new framework.
The public comment period, which will last until June 13 or 29, offers medical professionals and CBD businesses the opportunity to examine the draft order and voice their concerns before a final decision is made and the amendments can be enacted.
Opinions are now being solicited on five topics, including law enforcement, THC analysis methods, the development of related laws and regulations, and first and second-class cultivation license reviews.
As previously reported, the bill is set to amend a few key measures which could enable the country’s CBD and medical cannabis industries to flourish.
Primarily, while Japan already has a booming CBD industry, it currently only allows products with no trace THC. This is expected to change, and initial reports suggest this could rise to 0.3%.
Organigram Signs 2nd UK Supply Deal With Avida Medical
Next PostCanopy Growth Trims Losses Significantly as It Prepares for Financial Boost From Rescheduling
Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, they have researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Related Posts
Related Posts
Dr Green Digital Key: The Claims, the Concerns, and Why We’re Investigating
After months of interviews, document reviews, blockchain analysis and regulatory consultation, we have found a growing chasm between the company’s...
Cronos Grows its International Footprint in Switzerland
Cronos Group announced today that it is expanding distribution with its PEACE NATURALS® medical cannabis brand in the Swiss market through...
SOMAÍ and Lusófona Publish Peer-Reviewed Study Showcasing Best Practices in Full-Spectrum Cannabis Oil Production
The New Federal Government Drugs Commissioner Remains Vague on the Cannabis Issue
FSA Shifts Gears: Reformulation, THC Tolerance, and Faster CBD Approvals Appear to Be On the Horizon
Small Island, Big Vision: Medical Cannabis as a Catalyst for Economic Growth
CONNECT
Related Posts
Related Posts
Dr Green Digital Key: The Claims, the Concerns, and Why We’re Investigating
After months of interviews, document reviews, blockchain analysis and regulatory consultation, we have found a growing chasm between the company’s...
Cronos Grows its International Footprint in Switzerland
Cronos Group announced today that it is expanding distribution with its PEACE NATURALS® medical cannabis brand in the Swiss market through...
SOMAÍ and Lusófona Publish Peer-Reviewed Study Showcasing Best Practices in Full-Spectrum Cannabis Oil Production
The study validates SOMAÍ’s patent-pending process for producing Full-Spectrum Extract Cannabis Oil (FECO), offering new scientific evidence that bridges pharmaceutical...
The New Federal Government Drugs Commissioner Remains Vague on the Cannabis Issue
With the appointment of Prof. Dr. Hendrik Streeck as the new Federal Government Commissioner for Drugs, Burkhard Blienert had to...
FSA Shifts Gears: Reformulation, THC Tolerance, and Faster CBD Approvals Appear to Be On the Horizon
This morning, the UK’s Food Standards Agency (FSA) announced some significant updates to its multi-year CBD Novel Foods approvals process,...
Recent Posts
Related Posts
FSA Shifts Gears: Reformulation, THC Tolerance, and Faster CBD Approvals Appear to Be On the Horizon
This morning, the UK’s Food Standards Agency (FSA) announced some significant updates to its multi-year CBD Novel Foods approvals process,...
Pharmaceutical Cannabis Steps Into the Spotlight as DanCann, Phytanix and Sandoz Unveil Major Moves
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the...
Precision Over Potency: Personalised Cannabis Medicine is Coming of Age
One of the key differences between medical cannabis and other more traditional treatments is the highly personalised nature of how...
Full-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2...
Italy’s Hemp Industry Dealt 2nd Major Blow as CBD Oil Classified as Narcotic
Italy’s hemp industry has been dealt another major blow this week as the Regional Administrative Court (TAR) rejected an appeal,...
Subscribe to our mailing list to receives daily updates!
We won’t spam you
Categories
Browse by Tags